Friedreich ataxia (FRDA) is an autosomal recessive degenerative disease caused by insufficient expression of frataxin (FXN), a mitochondrial iron-binding protein required for Fe-S cluster assembly. The development of treatments to increase FXN levels in FRDA requires elucidation of the steps involved in the biogenesis of functional FXN. The FXN mRNA is translated to a precursor polypeptide that is transported to the mitochondrial matrix and processed to at least two forms, FXN Friedreich ataxia (FRDA) 2 (OMIM number 229300) is an autosomal recessive disease with an estimated incidence of 1:40,000. Most FRDA patients are apparently healthy at birth and during the first 5-10 years of life; then their gait becomes increasingly unsteady and wide-based and their voluntary movements uncoordinated. Many patients develop hypertrophic cardiomyopathy as well as diabetes, muscle weakness, and skeletal deformities. Although cognitive functions remain largely intact during disease progression, patients develop significant communication difficulties due to dysarthria, which is often compounded by vision and hearing loss. The majority of patients eventually become wheelchair-bound and dependent on others for most daily activities. Cardiac failure is a frequent cause of death at a young age (1).The FRDA locus encodes a mitochondrial protein designated frataxin (FXN), which is expressed at much lower levels in FRDA patients compared with normal individuals (2). In most patients, FXN deficiency results from the presence of an expanded GAA repeat in the first intron of the FRDA gene (2) that causes transcriptional silencing (reviewed in Ref.3). Although FXN is ubiquitously expressed, certain cells (dorsal root ganglia neurons, cardiomyocytes, and pancreatic beta cells) are exquisitely sensitive to frataxin depletion, and the degenerative loss of these particular cells accounts for the major clinical aspects of FRDA (1).Extensive biochemical studies have shown that frataxins across species are conserved iron-binding proteins that can either provide iron for Fe-S cluster assembly and heme synthesis or store iron as a stable mineral (reviewed in Ref. 4). The loss of these properties accounts for impaired iron utilization and increased iron toxicity linked to frataxin deficiency in the mitochondria of such diverse organisms as Saccharomyces cerevisiae, Drosophila, mouse, and humans (5-8). In humans, the mitochondrial alterations caused by FXN deficiency lead to tissue-specific changes in various cellular pathways involved in antioxidant, metabolic, and inflammatory responses, thereby amplifying the pathophysiology of FRDA and promoting disease progression (9 -13).